http://www.nytimes.com/2002/07/11/health/11WYET.html
oving
quickly to try to prevent women from stopping their hormone replacement
treatments because of fear of breast cancer, the Wyeth company has sent 500,000
letters to doctors and other health care providers urging them to consider when
they talk to patients the "critical role" that one of its products, Prempro, has
in relieving the symptoms of menopause.
|
Advertisement
|
 |
A spokesman for Wyeth, Douglas Petkus, said the company began sending the letters on Tuesday, soon after researchers announced that they had halted a large study of the long-term use of Prempro.
The researchers stopped the study of the drug, a combination of estrogen and progestin that six million women take, after finding that it caused small increases in breast cancer, heart attacks, strokes and blood clots.
The letter provides a glimpse at how Wyeth hopes to hold onto sales of Prempro and its related hormone therapy drug, Premarin, which generated more than $2 billion in sales for the company last year.
The letter tries to differentiate between women who take Prempro for more than four years, the point where researchers found a higher risk of breast cancer, and those who took it for less time. The letter urges doctors to consider Prempro's benefits of relieving hot flashes and other problems in healthy women who begin the therapy early in menopause.
Wyeth appears to be trying to keep any loss of sales limited to women who take Prempro for four years or longer. To reduce fears, Wyeth also points out that the risks of breast cancer and heart problems had already been found in other studies and included in Prempro's labeling.
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.